Thus, we speculated that SHP2 may stimulate the occurrence of diabetes‐related liver cancer, whereas SHP2 silencing could inhibit IRS‐2 phosphorylation by regulating the activation of AKT and ERK1/2, thus ameliorating glucose uptake and IR. The gene discussed is MAPK3; the disease is liver cancer.